ClinicalTrials.Veeva

Menu
C

Chesapeake Clinical Research, Inc. | White Marsh, MD

Research site
About
High level, experienced asthma/allergy/immunology site. Extensive experience in asthma, sinusitis, nasal polyposis, allergic rhinitis, eosinophilic disorders, urticaria and atopic dermatitis. We also work on vaccine trials and respiratory viral diseases.

Site insights

Top conditions

Top treatments

MK-7264
UPB-101
Gefapixant
PF-04965842
Verekitug
CDX-0159
Rocatinlimab
BAY1817080
DUPIXENT®
MK-7264-043

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Jonathan Matz

Verified by this site

Active trials

8 of 20 total trials

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in...

Active, not recruiting
Chronic Spontaneous Urticaria
Biological: barzolvolimab
Drug: Matching Placebo

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Enrolling
Asthma
Drug: Placebo
Drug: Rocatinlimab

This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism...

Enrolling
Chronic Inducible Urticaria
Drug: Oral EVO756

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal pol...

Enrolling
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Drug: Standard therapy for INCS
Drug: LY3650150

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate t...

Enrolling
Severe Asthma
Drug: Placebo
Drug: Verekitug (UPB-101)

The primary purpose of this study is to assess the effect of verekitug (UPB-101) on the endoscopically determined size and extend of nasal polyps in...

Enrolling
Chronic Rhinosinusitis with Nasal Polyps
Drug: Placebo
Drug: Verekitug (UPB-101)

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urtica...

Enrolling
Chronic Spontaneous Urticaria
Drug: Placebo
Drug: Oral EP262

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Trial sponsors

Allergy Therapeutics logo
Merck Sharp & Dohme (MSD) logo
Pfizer logo
U
A
Amgen logo
Avillion logo
Bayer logo
B
Celldex Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems